Fulvestrant (Faslodex)

From HemOnc.org - A Hematology Oncology Wiki
Jump to: navigation, search

General information

Class/mechanism: Estrogen receptor antagonist; competitively binds to the estrogen receptor (ER) and downregulates estrogen receptor expression.[1][2][3]
Route: IM
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication


  1. 1.0 1.1 1.2 Fulvestrant (Faslodex) package insert
  2. Fulvestrant (Faslodex) package insert (locally hosted backup)
  3. Faslodex manufacturer's website
  4. Fulvestrant (Faslodex) patient drug information (Chemocare)
  5. Fulvestrant (Faslodex) patient drug information (UpToDate)